OBJECTIVE: To present a pooled analysis of the efficacy of rituximab from European cohorts
diagnosed with biopsy-proven lupus nephropathy (LN) who were treated with rituximab …

OBJECTIVE: Mixed cryoglobulinemia syndrome (MCs) is a systemic vasculitis characterized
by multiple organ involvement due to the vascular deposition of immune-complexes, mainly …

Background: B-cell depletion with rituximab is commonly used for patients with systemic
lupus erythematosus (SLE) that is refractory to conventional therapy, but it yields variable …

Objective To assess factors associated with primary and secondary non-response to
rituximab in systemic lupus erythematosus (SLE) and evaluate management of secondary …

Objective Conventional treatment of systemic lupus erythematosus (SLE) and lupus
nephritis (LN) is associated with damage accrual, hence increased morbidity rate. Off-label …

As in previous years, the consensus group to consider the use of biological agents in the
treatment of rheumatic diseases met during the 13th Annual Workshop on Advances in …

The wide spectrum of clinical manifestations and high relapse rate represent a therapeutic
challenge in systemic lupus erythematosus (SLE). Observational studies suggested efficacy …

Introduction Health-related quality of life (HRQOL) is affected by numerous clinical variables,
including disease activity, damage, fibromyalgia, depression and anxiety. However, these …

Objective To evaluate whether rituximab at a low dose of 250 mg/m 2× 2 may be as effective
as at higher dosages, most commonly 375 mg/m 2× 4, used in previous studies on the …

Introduction Few treatment options exist for patients with systemic lupus erythematosus
(SLE) who fail conventional therapy. Although widely used to treat lupus, the efficacy of B …